CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the CAR T pipeline finds companies are exploring a wide range of not-yet-validated targets and historically tough indications.

CAR T therapies for solid tumors have lagged those for hematologic malignancies for a constellation of reasons, including intratumoral heterogeneity, lack of tumor-specific target antigens, and an immunosupressive microenvironment...